Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

Clicks: 438
ID: 118752
1997
RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI.
Reference Key
wj1997pediatricsrespiratory Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rodriguez WJ;Gruber WC;Welliver RC;Groothuis JR;Simoes EA;Meissner HC;Hemming VG;Hall CB;Lepow ML;Rosas AJ;Robertsen C;Kramer AA;;
Journal pediatrics
Year 1997
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9041304
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support u.s. gov't Child Infant newborn P.H.S. preschool risk factors Clinical Trial Randomized Controlled Trial Double-Blind Method follow-up studies immunoglobulins intravenous / therapeutic use* comment pneumonia hospitalization human / immunology respiratory syncytial virus infections / therapy* respiratory syncytial virus heart defects respiratory syncytial virus infections / complications viral / virology premature viral / complications bronchiolitis / virology viral / therapy* w c gruber pmid:9041304 doi:10.1542/peds.99.3.454 w j rodriguez a a kramer bronchiolitis / complications bronchiolitis / therapy* bronchopulmonary dysplasia / complications congenital / complications

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.